What is the appropriate dose of enoxaparin (Clexane) for an 80‑kg adult requiring therapeutic anticoagulation?

Enoxaparin Dosing for an 80 kg Adult Requiring Therapeutic Anticoagulation

For an 80 kg adult requiring therapeutic anticoagulation, administer enoxaparin 80 mg (1 mg/kg) subcutaneously every 12 hours, assuming normal renal function (creatinine clearance ≥30 mL/min). 1, 2, 3

Standard Therapeutic Dosing

• The established therapeutic dose is 1 mg/kg subcutaneously every 12 hours for patients with creatinine clearance >30 mL/min 1, 2, 3
• For an 80 kg patient, this translates to 80 mg subcutaneously every 12 hours 1, 2, 3
• Alternative once-daily dosing of 1.5 mg/kg (120 mg for 80 kg) can be used in select situations, though twice-daily dosing is preferred for most acute thrombotic conditions 2

Critical Dose Adjustments Based on Renal Function

If creatinine clearance is <30 mL/min, reduce the dose to 1 mg/kg (80 mg) subcutaneously once daily (a 50% dose reduction from standard twice-daily dosing). 4

• Standard twice-daily dosing in severe renal impairment increases major bleeding risk by 3.9-fold (OR 3.88; 95% CI 1.78-8.45) 4
• Enoxaparin clearance decreases by approximately 44% when creatinine clearance falls below 30 mL/min, leading to drug accumulation 4
• The once-daily regimen maintains therapeutic anti-Xa activity while eliminating excess bleeding risk (OR 0.58; 95% CI 0.09-3.78) 4

Age-Specific Renal Adjustments

• Patients <75 years with CrCl <30 mL/min receiving fibrinolytic therapy: Give 30 mg IV bolus followed by 1 mg/kg subcutaneously once daily 1, 4
• Patients ≥75 years with CrCl <30 mL/min: Omit the IV bolus and give 1 mg/kg subcutaneously once daily 1, 4

Duration of Therapy

Continue enoxaparin for the duration of hospitalization, up to a maximum of 8 days, or until definitive intervention (e.g., PCI, CABG) is performed, whichever comes first. 4

• This 8-day ceiling is supported by Level A evidence from the ESSENCE and TIMI 11B trials 3, 4
• After uncomplicated PCI, discontinue enoxaparin immediately 4
• If CABG is planned, stop enoxaparin 12-24 hours before surgery to reduce perioperative bleeding risk 4

Monitoring Recommendations

Routine anti-Xa level monitoring is NOT required for standard therapeutic dosing in patients without severe renal impairment, obesity, or pregnancy. 5, 4

• Anti-Xa monitoring should be considered only if clinically significant bleeding occurs, drug accumulation is suspected, or in patients with borderline renal function 5, 4
• When monitoring is performed, draw the anti-Xa level 4-6 hours after the third or fourth dose 4
• Target therapeutic range: 0.5-1.0 U/mL for twice-daily dosing 6

Special Populations

Obesity (BMI ≥40 kg/m² or weight >100 kg)

• Use actual body weight for dosing calculations without a maximum dose cap 5, 6
• Standard 1 mg/kg dosing based on actual body weight achieves therapeutic anti-Xa levels in 56% of obese patients, with 40% supratherapeutic and only 4% subtherapeutic 6
• Consider reduced dosing (0.75-0.85 mg/kg) in morbidly obese patients, as this achieves therapeutic levels in 66% versus only 42% with standard dosing 7, 8
• Do not routinely monitor anti-Xa levels in obesity unless clinical risk factors for bleeding are present 5, 6

Low Body Weight (<50 kg)

• For prophylactic dosing in patients <50 kg with severe renal impairment, use 30 mg once daily to mitigate accumulation and bleeding risk 4
• Therapeutic dosing should still be weight-based (1 mg/kg every 12 hours) but monitor closely for bleeding 9

Critical Clinical Pitfalls to Avoid

• Do NOT use standard twice-daily dosing (1 mg/kg every 12 hours) in patients with CrCl <30 mL/min—this markedly increases bleeding risk without improving efficacy 4
• Do NOT switch between enoxaparin and unfractionated heparin during active treatment—such transitions increase bleeding risk 4
• Do NOT use fondaparinux as an alternative in patients with CrCl <30 mL/min—it is contraindicated 4
• Do NOT administer enoxaparin within 12 hours before neuraxial anesthesia or spinal puncture—risk of spinal hematoma 10
• Do NOT give the first dose sooner than 1 hour after needle/catheter placement for neuraxial procedures 2

Alternative Anticoagulants When Enoxaparin Is Contraindicated

Unfractionated Heparin (UFH)

• UFH does not accumulate in renal dysfunction and is preferred in unstable renal function or when rapid reversibility is needed 4
• Dosing: 80 U/kg IV bolus, then 18 U/kg/h IV infusion, titrated to aPTT 1.5-2.0 times control 1, 2, 4

Dalteparin

• Dalteparin 5,000 IU once daily for prophylaxis does not bio-accumulate in CrCl <30 mL/min 4
• Therapeutic dosing: 200 IU/kg once daily or 100 IU/kg every 12 hours 2

Fondaparinux

• Contraindicated when CrCl <30 mL/min 4
• Dosing for CrCl ≥30 mL/min: <50 kg: 5 mg daily; 50-100 kg: 7.5 mg daily; >100 kg: 10 mg daily 2

Context-Specific Dosing Scenarios

Acute Coronary Syndrome (STEMI/NSTEMI)

• With primary PCI: 0.5 mg/kg IV bolus (40 mg for 80 kg patient) 1
• With fibrinolytic therapy (age <75 years): 30 mg IV bolus followed by 1 mg/kg subcutaneously every 12 hours (80 mg for 80 kg patient) 1
• With fibrinolytic therapy (age ≥75 years): No IV bolus; start with 0.75 mg/kg subcutaneously every 12 hours (60 mg for 80 kg patient) 1

Venous Thromboembolism Treatment

• Standard regimen: 1 mg/kg every 12 hours (80 mg for 80 kg patient) 2, 11
• Alternative once-daily: 1.5 mg/kg once daily (120 mg for 80 kg patient) 2
• Long-term treatment: Transition to oral anticoagulation after initial parenteral therapy 2

VTE Prophylaxis (Hospitalized Medical/Surgical Patients)

• Standard prophylactic dose: 40 mg once daily 2
• High-risk surgical patients: Consider extended prophylaxis for up to 4 weeks 2
• CrCl <30 mL/min: Reduce to 30 mg once daily 4